Jiuzhitang Maker has been selected as one of the Top 10 Key Enterprises by the Development and Reform Commission of Daxing District and the management committee of the Biomedicine Industry Park, and have been awarded titles including “ZGC High-Tech Enterprise”, “National High-Tech Enterprise”, “ZGC Gold Seed Enterprise” and “Postdoctoral Station”. “A Pre-clinical Study Using Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat Acute Cerebral Stroke” and “Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Lung Injuries Caused by COVID-19”, two research projects JZT Maker plans to launch were both approved by relevant authorities, and received fund support from Beijing Science and Technology Major Project initiative, Daxing District Program for Better Development of the Healthcare Industry, the COVID-19 Epidemic Prevention and Control project under Daxing Science and Technology Commission initiative and Daxing District Program for Advancing Transfer and Transformation of Technological Achievements.


Stemedica Cell Technologies, Inc. is the first US company with approval to treat Alzheimer’s using stem cells, and a clinical grade stem cell manufacturer holding a Drug Manufacturing License issued by the government of California, USA.